Large Molecule Drug Substance CDMO Market to Grow with a CAGR of 9.40% through 2029
Increase in the demand of personalized medicine and targeted therapies and focus on core competencies is expected to drive the
Global Large Molecule Drug Substance CDMO Market growth in the forecast period,
2025-2029.
According to
TechSci Research report, “Large Molecule Drug Substance CDMO Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”,
the Global Large Molecule Drug Substance CDMO Market stood at USD 11.60 billion
in 2023 and is anticipated to grow with a CAGR of 9.40% through 2029. Increased awareness among individuals regarding Large Molecule Drug Substance Contract Development and Manufacturing Organizations (CDMOs) has created favorable market conditions for the global Large Molecule Drug Substance CDMOs market. Various factors contribute to the growth of different Large Molecule Drug Substance CDMO products.
The rising demand for biologic drugs and biosimilars stands out as a significant driver for the expansion of the Global Large Molecule Drug Substance CDMO market. Biologics, including monoclonal antibodies, therapeutic proteins, and vaccines, have gained prominence due to their effectiveness in treating various complex diseases. As research and development efforts continue to focus on biologics, pharmaceutical companies increasingly outsource their manufacturing processes to specialized CDMOs. These CDMOs possess the technical expertise and advanced facilities required for large-scale biologic production, ensuring cost-efficiency and regulatory compliance.
Collaborating with CDMOs enables these companies to access state-of-the-art facilities and a skilled workforce capable of navigating the challenges of large molecule drug substance production. Regulatory authorities such as the FDA and EMA impose stringent guidelines to ensure the safety, efficacy, and quality of biologic drugs. CDMOs are well-equipped to adhere to these regulations, making them indispensable partners for pharmaceutical companies aiming to bring their large molecule drug candidates to market, thereby further stimulating market growth.
The intricate nature of large molecule drug substance production necessitates specialized facilities, advanced technologies, and adherence to stringent regulatory guidelines. CDMOs possess the technical know-how and regulatory expertise to ensure compliant and efficient manufacturing processes.
Large Molecule Drug Substance Contract Development and Manufacturing Organizations (CDMOs) have assumed a crucial role in the pharmaceutical and biotechnology industries over recent years. These specialized entities play an integral part in the development, production, and manufacturing of large molecule drug substances. Large molecule drugs have gained significant prominence due to their effectiveness in treating complex and often chronic diseases. Technical complexities and expertise gaps may present challenges to market growth. Issues related to quality control and supply chain vulnerabilities could pose obstacles to the market in the near future.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Large Molecule Drug Substance CDMO Market”
The Global Large
Molecule Drug Substance CDMO Market is segmented into service, source, end user, regional distribution, and company.
Based on its service, the contract manufacturing emerged as the dominating segment in the global market for Large Molecule Drug Substance Contract Development and Manufacturing Organizations (CDMO) in 2023. The expansion can be attributed to various factors propelling pharmaceutical companies to outsource manufacturing processes to specialized CDMOs.
Pharmaceutical firms increasingly turn to CDMOs to capitalize on their expertise and infrastructure for large molecule drug substance production. CDMOs offer a comprehensive range of services, including process development, manufacturing, scale-up, and analytical testing, freeing pharmaceutical companies to concentrate on their core strengths such as research and commercialization. The contract manufacturing sector benefits from its flexibility and cost-efficiency, providing pharmaceutical companies access to cutting-edge facilities and specialized equipment without significant capital outlay. This adaptability allows pharmaceutical firms to respond to changing demand dynamics and expedite the introduction of new therapies to market.
Major companies
operating in Global Large Molecule Drug Substance CDMO Market are:
- Eurofins Scientific (Ireland) Limited
- WuXi Biologics Co., Ltd.
- Samsung Biologics Co Ltd
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics GmbH (AGC Inc. Group)
- Recipharm AB
- Siegfried Holding AG
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The progression in Bioprocessing Technologies and Automation, coupled with the rising demand for Biologics and Biosimilars, serves as pivotal catalysts for the large molecule drugs substance CDMO market. Recent years have witnessed the integration of advanced bioprocessing technologies and automation, enhancing production efficiency, quality control, and data-driven decision-making. CDMOs actively embrace these technologies to streamline large molecule drug substance manufacturing processes. The increasing emphasis on preventive healthcare products among consumers has spurred intensified production and marketing endeavors. In response to market demands, manufacturers are increasingly integrating cutting-edge technologies characterized by high production efficiency. With growing consumer acceptance and a continuous stream of product innovation, the Large Molecule Drug Substance CDMO market is poised for sustained growth in the foreseeable future”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.
“Large Molecule Drug Substance CDMO Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Service (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial, Others), By End User (Biotech Companies, CRO, Others), By Region, Competition, 2019-2029F”,
has evaluated the future growth potential of Global Large Molecule Drug
Substance CDMO Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Large Molecule Drug
Substance CDMO Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com